
Science Corporation Raises $400M at $3.5B Value
The brain-chip company's PRIMA device is approved in Europe and is now pursuing a U.S. route through the FDA.
Live Poll
Would you trust a brain implant to treat a serious medical condition?
U.S. biotechnology coverage addresses clinical research, regulatory pathways, funding and the national industry shaping how biological discoveries become products. Reporting here follows what advances and what stops it.

The brain-chip company's PRIMA device is approved in Europe and is now pursuing a U.S. route through the FDA.
Live Poll
Would you trust a brain implant to treat a serious medical condition?
November 15, 2026
BillionToOne Raises Revenue Outlook, Plans Blood TestThe company's oncology diagnostics business is growing while keeping accumulated losses small relative to public peers, and its blood-draw test is planned for December 2026.
November 13, 2026
Vir Biotech Raises $150 Million in Stock OfferingThe $10.00-per-share offering funds the company's pipeline, with underwriters holding an option on 2.25 million more shares.
November 12, 2026
Drugmaker Merges Research and Development UnitsThe combined unit, effective January 1, 2027, follows a structure already used by several large drugmakers and aims to speed decisions.
November 7, 2026
10x Genomics Lifts Atera Shipment Target to 50Atera began global commercial shipments in September, and the company now expects to ship about 50 instruments by year-end 2026.
November 7, 2026
Arcturus Loss Narrows on One-Time Partner PaymentThe $12 million termination payment from the CSL Seqirus deal, not operating gains, drove the quarter's smaller loss.
November 6, 2026
Iovance Cell Therapy Revenue Jumps 80%Growing Amtagvi sales narrow losses for a commercial-stage melanoma treatment already on the market.
November 6, 2026
Merck Drops IL-2 Cancer Candidate MK-1484The discontinued research-stage drug was tested alone and with Keytruda in solid tumors.
November 6, 2026
Colossal Sues Ex-Executive Over Alleged Trade SecretsThe lawsuit alleges the same knowhow underpins Colossal's de-extinction work and a rival medicine-manufacturing start-up.
November 6, 2026
Engineered Immune Molecules Show Preclinical PromiseEarly animal and cell data from BriaCell suggest a path for broader cancer immunotherapy, but human trials have not yet begun.
November 6, 2026
PacBio Narrows 2026 Revenue Outlook Amid Funding StrainLower academic and government funding in the Americas and slow China recovery are pressuring the sequencing company's 2026 forecast.
The beat runs across clinical trial results and their regulatory submissions, gene therapy and CRISPR program development, genomics platform adoption, biotech funding and acquisition, and the agency review processes that determine what reaches patients. It explains what a trial result demonstrates and what a regulatory decision requires next. Approval timelines shape the sector's commercial structure more than any single scientific finding because they determine when a therapy becomes a marketable product. Acquisition activity receives sustained attention since it regularly determines which research programs survive and which are discontinued.